References
- Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis 2015;6:304–313.
- Bae Y, Kang SH, Park JO, et al. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergol Int 2020;69:304–306.
- Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017;72:519–533.
- Labrador-Horrillo M, Ferrer M. Profile of omalizumab in the treatment of chronic spontaneous urticaria. Drug Des Devel Ther 2015;9:4909–4915.
- Deza G, Ricketti PA, Giménez-Arnau AM, et al. Emerging biomarkers and therapeutic pipelines for chronic spontaneous urticaria. J Allergy Clin Immunol Pract 2018;6:1108–1117.
- Acer E, Kaya Erdogan H, Yuksel CN, et al. The effect of omalizumab on hematological and inflammatory parameters in patients with chronic spontaneous urticaria. Cutan Ocul Toxicol 2019;38:5–8.
- Önder S, Ozturk M. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria? Cutan Ocul Toxicol 2020;39:31–35.
- Djordjevic D, Rondovic G, Surbatovic M, et al. Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-tolymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: which ratio to choose to predict outcome and nature of bacteremia?. Mediators Inflamm 2018;2018:3758068.
- Jörg L, Pecaric-Petkovic T, Reichenbach S, et al. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients. Clin Exp Allergy 2018;48:196–204.
- Maurer M, Raap U, Staubach P, et al. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study. Clin Exp Allergy 2019;49:655–662.
- Puxeddu I, Pratesi F, Ribatti D, et al. Mediators of inflammation and angiogenesis in chronic spontaneous urticaria: are they potential biomarkers of the disease? Mediators Inflamm 2017;2017:4123694.
- Asero R, Cugno M, Tedeschi A. Eosinophils in chronic urticaria: supporting or leading actors?. World Allergy Organ J 2009;2:213–217.
- Navinés-Ferrer A, Serrano-Candelas E, Molina-Molina GJ, et al. IgE-related chronic diseases and anti-IgE-based treatments. J Immunol Res 2016;2016:8163803.
- Tamer F, Erdogan FG, Dincer Rota D, et al. Efficacy of omalizumab in patients with chronic spontaneous urticaria and its association with serum IgE levels and eosinophil count. Acta Dermatovenerol Croat 2019;27:101–106.
- Kasperska-Zając A, Grzanka A, Jarzab J, et al. The association between platelet count and acute phase response in chronic spontaneous urticaria. Biomed Res Int 2014;2014:650913.
- Folci M, Heffler E, Canonica GW, et al. Cutting edge: biomarkers for chronic spontaneous urticaria. J Immunol Res 2018;2018:5615109.
- Magen E, Mishal J, Zeldin Y, et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci 2010;339:504–508.
- Ertas R, Ozyurt K, Karakukcu C, et al. Evaluation of platelet parameters and neutrophil/lymphocyte ratio during omalizumab treatment in patients with severe chronic spontaneous urticaria. Turk J Med Sci 2018;48:1255–1262.
- Chandrashekar L, Rajappa M, Sundar I, et al. Platelet activation in chronic urticaria and its correlation with disease severity. Platelets 2014;25:162–165.